TABLE 2.
Resistance and non-wild-type antifungals pattern of New Jersey C. auris clinical isolates from 2017 through 2020
| Year and total no. of isolates | 2017 (12) |
2018 (13) |
2019 (48) |
2020 (61) | P value | ||
|---|---|---|---|---|---|---|---|
| Antifungal | CDC BP | ECV UL-WT | % (n) resistance/non-wild-type | ||||
| FLC | ≥ 32 | - | 100% (12) | 100% (13) | 100% (48) | 100% (61) | 1 |
| ITC | - | 2 | 0 | 7.7% (1) | 0 | 0 | 0.1852 |
| ISA | - | 2 | 0 | 7.7% (1) | 0 | 14.8% (9) | 0.01613 |
| POS | - | 0.5 | 0 | 15.4% (2) | 18.7% (9) | 47.5% (29) | 0.0002489 |
| VRC | - | 4 | 8.3% (1) | 7.7% (1) | 2.1% (1) | 4.9% (3) | 0.3546 |
| AFG | ≥ 4 | - | 0 | 0 | 0 | 0 | 1 |
| CAS | ≥ 2 | - | 0 | 0 | 0 | 0 | 1 |
| MFG | ≥ 4 | - | 0 | 0 | 0 | 0 | 1 |
| AMB | ≥ 2 | - | 66.7% (8) | 46.2% (6) | 43.7% (21) | 31.1% (19) | 0.1108 |